33 Jahre DRFZ: Epidemiologie und Versorgungsforschung

[1]  K. Minden,et al.  Clinical manifestations and outcome of SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases: data from the National Paediatric Rheumatology Database in Germany , 2021, RMD Open.

[2]  C. Demetriou,et al.  POS1162 PREDICTORS OF HOSPITALISATION IN PATIENTS WITH RHEUMATIC DISEASE AND COVID-19 IN IRELAND: DATA FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY , 2021, Annals of the Rheumatic Diseases.

[3]  L. Trupin,et al.  Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry , 2021, Annals of the Rheumatic Diseases.

[4]  K. Minden,et al.  Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis , 2021, Arthritis Research & Therapy.

[5]  R. Fischer-Betz,et al.  Pregnancy in women with psoriatic arthritis: A systematic literature review of disease activity and adverse pregnancy outcomes. , 2021, Seminars in arthritis and rheumatism.

[6]  M. Gianfrancesco,et al.  Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Mulhearn et al , 2021, Annals of the Rheumatic Diseases.

[7]  L. Trupin,et al.  Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry , 2021, Annals of the Rheumatic Diseases.

[8]  F. Hoffmann,et al.  Use of Physical Therapy in Patients With Osteoarthritis in Germany: An Analysis of a Linkage of Claims and Survey Data , 2020, Arthritis care & research.

[9]  Matthew Rowland,et al.  Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed , 2020, The Lancet.

[10]  J. Listing,et al.  Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis , 2019, Rheumatology.

[11]  A. Zink,et al.  Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. , 2019, Rheumatology.

[12]  K. Minden,et al.  Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry. , 2019, Rheumatology.

[13]  A. Zink,et al.  Long-term trends in rheumatology care , 2019, Zeitschrift fur Rheumatologie.

[14]  Matthias Schneider,et al.  Are prognostic factors adequately selected to guide treatment decisions in patients with rheumatoid arthritis? A collaborative analysis from three observational cohorts. , 2019, Seminars in arthritis and rheumatism.

[15]  T. Dörner,et al.  Trends in employment and hospitalisation in patients with Sjögren's syndrome 1996-2016: results from the German National database. , 2019, Clinical and experimental rheumatology.

[16]  K. Minden,et al.  Time of Disease‐Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug‐Free Remission in Young Adulthood , 2019, Arthritis care & research.

[17]  A. Zink,et al.  [Non-drug treatment of rheumatoid arthritis : An analysis of claims data and a survey of insured persons (Project PROCLAIR)]. , 2019, Zeitschrift für Rheumatologie (Print).

[18]  K. Minden,et al.  Participation in school sports among children and adolescents with juvenile idiopathic arthritis in the German National Paediatric Rheumatologic Database, 2000–2015: results from a prospective observational cohort study , 2019, Pediatric Rheumatology.

[19]  A. Zink,et al.  [Long-term trends in rheumatology care : Achievements and deficits in 25 years of the German national rheumatology database]. , 2019, Zeitschrift für Rheumatologie (Print).

[20]  A. Zink,et al.  [Cost of illness in axial spondylarthritis for patients with and without tumor necrosis factor inhibitor treatment: results of a routine data analysis]. , 2019, Zeitschrift fur Rheumatologie.

[21]  F. Hoffmann,et al.  Nichtmedikamentöse Versorgung der rheumatoiden Arthritis , 2018, Zeitschrift für Rheumatologie (Print).

[22]  A. Heiligenhaus,et al.  The majority of patients with newly diagnosed juvenile idiopathic arthritis achieve a health-related quality of life that is similar to that of healthy peers: results of the German multicenter inception cohort (ICON) , 2018, Arthritis Research & Therapy.

[23]  A. Zink,et al.  Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data , 2018, Annals of the rheumatic diseases.

[24]  K. Minden,et al.  Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA , 2018, Annals of the rheumatic diseases.

[25]  A. Krause,et al.  Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort , 2017, Rheumatology International.

[26]  K. Minden,et al.  Transition to adult rheumatology care is necessary to maintain DMARD therapy in young people with juvenile idiopathic arthritis. , 2017, Seminars in arthritis and rheumatism.

[27]  W. Dixon,et al.  Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project , 2017, Annals of the rheumatic diseases.

[28]  A. Zink,et al.  Rheumatologic care of nursing home residents with rheumatoid arthritis: a comparison of the year before and after nursing home admission , 2017, Rheumatology International.

[29]  J. Listing,et al.  Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort , 2017, Annals of the rheumatic diseases.

[30]  M. Aringer,et al.  Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs , 2016, Annals of the rheumatic diseases.

[31]  W. Dixon,et al.  Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers , 2016, Annals of the rheumatic diseases.

[32]  K. Minden,et al.  Outcome and Trends in Treatment of Systemic Juvenile Idiopathic Arthritis in the German National Pediatric Rheumatologic Database, 2000–2013 , 2016, Arthritis & rheumatology.

[33]  J. Listing,et al.  Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis , 2016, Arthritis Research & Therapy.

[34]  D. Huscher,et al.  Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases , 2016, Arthritis Research & Therapy.

[35]  A. Heiligenhaus,et al.  Impact of Antiinflammatory Treatment on the Onset of Uveitis in Juvenile Idiopathic Arthritis: Longitudinal Analysis From a Nationwide Pediatric Rheumatology Database , 2015, Arthritis care & research.

[36]  J. Listing,et al.  Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis , 2015, Annals of the rheumatic diseases.

[37]  K. Minden,et al.  Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA) , 2014, Annals of the rheumatic diseases.

[38]  K. Minden,et al.  Prevalence of overweight in children and adolescents with juvenile idiopathic arthritis , 2015, Scandinavian journal of rheumatology.

[39]  Matthias Schneider,et al.  Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT , 2015, Rheumatology.

[40]  D. Huscher,et al.  Trends in treatment and outcomes of ankylosing spondylitis in outpatient rheumatological care in Germany between 2000 and 2012 , 2015, RMD Open.

[41]  G. Schett,et al.  Depression is a stronger predictor of the risk to consider work disability in early arthritis than disease activity or response to therapy , 2015, RMD Open.

[42]  D. Huscher,et al.  Evolution of cost structures in rheumatoid arthritis over the past decade , 2014, Annals of the rheumatic diseases.

[43]  G. Burmester,et al.  Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab , 2013, Annals of the rheumatic diseases.

[44]  D. Huscher,et al.  Changes in referral, treatment and outcomes in patients with systemic lupus erythematosus in Germany in the 1990s and the 2000s , 2014, Lupus Science & Medicine.

[45]  A. Krause,et al.  Evaluation of the RABBIT Risk Score for serious infections , 2013, Annals of the rheumatic diseases.

[46]  T. Dörner,et al.  Fatigue and depression predict physician visits and work disability in women with primary Sjögren's syndrome: results from a cohort study. , 2012, Rheumatology.

[47]  M. Eveslage,et al.  Extended Report , 2011 .

[48]  W. Dixon,et al.  The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. , 2011, Rheumatology.

[49]  D. Huscher,et al.  Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997–2007: results from the National Database of the German Collaborative Arthritis Centres , 2010, Annals of the rheumatic diseases.

[50]  G. Burmester,et al.  Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT , 2010, Arthritis research & therapy.

[51]  H. Raspe,et al.  Advance and unmet need of health care for patients with rheumatoid arthritis in the German population--results from the German Rheumatoid Arthritis Population Survey (GRAPS). , 2009, Rheumatology.

[52]  Matthias Schneider,et al.  Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? , 2008, Arthritis and rheumatism.

[53]  H. Zeidler,et al.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial , 2002, The Lancet.